FDA Approves Organon's Elocon Cream (Mometasone Furoate) for Dermatitis Treatment
Approval Background and Clinical Significance
The U.S. Food and Drug Administration (FDA) granted final approval for the New Drug Application (NDA 019625) of Elocon Cream 0.1% on May 6, 1987. Elocon was approved without convening a separate advisory committee (AdComm). Its active ingredient, mometasone furoate, selectively acts on intracellular glucocorticoid receptors. As a medium-potency topical corticosteroid, it offers higher receptor affinity and potent anti-inflammatory effects compared to existing formulations. Its once-daily application provides enhanced convenience for patients.
Clinical Efficacy and Differentiating Factors
In a Phase 3 clinical trial, Elocon Cream demonstrated equivalent or superior efficacy to betamethasone valerate 0.1% cream (a standard treatment administered twice daily) with only once-daily administration. In a multi-center clinical study involving patients with atopic dermatitis and psoriasis, Elocon Cream rapidly improved skin inflammation indicators such as erythema and pruritus. Reducing the number of applications by half significantly improved patient compliance, which is a key differentiating factor. This plays a crucial role in alleviating the long-term treatment burden for patients with chronic skin conditions.
Safety Profile and Patient Benefits
The safety profile, which minimizes the common side effects of steroids such as skin atrophy and suppression of the hypothalamic-pituitary-adrenal (HPA) axis, was a key factor in the approval. Elocon's high lipophilicity and rapid hepatic metabolism result in low systemic absorption, reducing the risk of systemic side effects. Based on this excellent safety profile, additional clinical data were subsequently collected, and the prescription age was expanded to include pediatric patients (2 years and older), maximizing its clinical utility. This provided a safe treatment option for healthcare professionals treating young children who require long-term use of topical agents.
Market Value and Ownership Changes
Elocon was a key product that drove sales growth for its original developer, Schering-Plough, and was subsequently transferred to Merck & Co. and then to Organon & Co. in 2021 through a spin-off. The global topical steroid market maintains stable growth at approximately $4 billion to $6 billion annually, and Elocon continues to maintain strong brand recognition even after patent expiration and increased generic competition. Organon is leveraging this legacy brand as a continuous cash cow to actively reinvest in new portfolios, including women's health.
The FDA approval of Elocon Cream established a standard for medium-potency topical steroids that deliver potent anti-inflammatory effects with once-daily administration. In Phase 3 clinical trials, it demonstrated equivalent or superior efficacy compared to the existing standard treatment, betamethasone valerate, and minimized systemic side effects such as hypothalamic-pituitary-adrenal (HPA) axis suppression, expanding the market to include pediatric patients. It maintains a strong presence in the global mometasone furoate market, valued at approximately $2.5 billion, and continues to demonstrate unique original brand power in price competition with generic manufacturers even after patent expiration. Organon & Co. (OGN), which was spun off from Merck & Co., has secured the financial resources to focus on investing in the development of new pipelines based on this stable cash cow brand.
Source: openFDA (api_fda)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=NDA019625